3 recruiting, 3 terminated, 2 completed, 1 withdrawn. 4 Phase 1, 3 Early Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Early Phase 1 | 3 | Recruiting 2, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Eben Rosenthal: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients 68Ga-FAPI-46 - Solid Tumor Cancer, Solid Tumor Malignancy | Early Phase 1 | Withdrawn | Eben Rosenthal | 2027-01-01 | 2026-01-21 | |
| Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures Panitumumab-IRDye800 - Meningioma, Glioblastoma | Early Phase 1 | Recruiting | Eben Rosenthal | 30 | 2026-07-07 | 2026-10-16 |
| Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) Nivolumab, Nivolumab-IRDye800 - Brain Cancer, HGG | Early Phase 1 | Recruiting | Eben Rosenthal | 38 | 2026-03-27 | 2026-07-01 |
| (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Eben Rosenthal | 60 | 2023-05-09 | 2026-05-08 |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer Panitumumab-IRDye800, Lymphoseek - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Completed | Eben Rosenthal | 3 | 2019-08-01 | 2022-11-10 |
| Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Cetuximab, Cetuximab-IRDye 800CW, Tumor resection - Brain Neoplasm, Malignant Glioma | Phase 1 / Phase 2 | Terminated | Eben Rosenthal | 3 | 2016-10-01 | 2020-03-31 |
| Panitumumab IRDye800 Optical Imaging Study Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM - Head and Neck Cancer | Phase 1 | Completed | Eben Rosenthal | 64 | 2016-08-01 | 2021-09-24 |
| Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery Cetuximab-IRDye800, Cetuximab - Pancreatic Adenocarcinoma | Phase 2 | Terminated | Eben Rosenthal | 8 | 2016-07-01 | 2019-06-25 |
| Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures Cetuximab-IRDye800 - Head and Neck Cancer | Phase 1 | Terminated | Eben Rosenthal | 1 | 2015-11-01 | 2019-06-24 |
Brain Neoplasms (3) · Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Glioma (2) · Neoplasms (2) · Glioblastoma (1) · Meningioma (1) · Neuroma, Acoustic (1) · Pituitary Neoplasms (1)
Cetuximab (2) · Antibodies, Monoclonal (1) · FAPI-46 (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Panitumumab (1) · Transurethral Resection of Bladder (1) · technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran (1)
United States (9)
Eben L Rosenthal, MD (1) · Fred M Baik (1) · George Poultsides, MD (1) · Gordon Li, MD (1) · Michael Topf, MD (1) · Patrick Kelly, MD (1) · Peter Morone, MD (1)
PMID 29667116, PMID 31421471, PMID 32416765, PMID 33078373, PMID 33168818
P30CA124435 (3), R01CA190306 (1)